Market Research Blog – Page 1154 – New Product Development

Radiation Toxicity Treatment Market Projected to Reach USD 5.58 Billion by 2029 at a 5.8% of CAGR

The global radiation toxicity treatment market was valued at approximately USD 3.55 billion in 2021 and is expected to grow significantly, reaching an estimated USD 5.58 billion by 2029, according to a recent market survey conducted by Future Market Insights (FMI). This growth reflects the increasing demand for effective treatments for radiation exposure, driven by a range of factors, including industrial applications, nuclear medicine, and concerns regarding nuclear safety.

Radiation toxicity can occur as a result of exposure to ionizing radiation from various sources, and the need for effective treatment solutions is more critical than ever. The rising incidence of conditions associated with radiation exposure is propelling the demand for innovative therapies and interventions in this field.

Key factors contributing to the anticipated growth of the radiation toxicity treatment market include:

Increasing Awareness of Radiation Risks: Growing awareness regarding the health risks associated with radiation exposure is driving the demand for effective treatment options, particularly among healthcare providers and patients.
Rising Incidence of Cancer: The increasing prevalence of cancer and the subsequent use of radiotherapy as a treatment option are boosting the demand for radiation toxicity management solutions.
Advancements in Treatment Technologies: Continuous innovations in treatment technologies and pharmaceuticals are enhancing the effectiveness of radiation toxicity treatments, making them more appealing to healthcare professionals.
Supportive Regulatory Frameworks: Government initiatives and regulatory support aimed at enhancing radiation safety and health care practices are expected to further stimulate market growth.

As the radiation toxicity treatment market continues to evolve, stakeholders are encouraged to focus on research and development to improve treatment efficacy and expand therapeutic options available to patients.

The past decade has witnessed a remarkable expansion in the installed base of internal radiation therapy machines, emerging as a key driver behind the industry’s surge. This growth can be attributed to the significant improvement in reimbursement scenarios and a favorable government policy framework in the field of cancer care. These advancements have enhanced the accessibility of radiation therapy, contributing significantly to the flourishing landscape of the Global Radiation Toxicity Treatment Industry.

According to the survey, major businesses in Asia Pacific will continue to invest extensively in the development of new radiation therapies, in response to the region’s rising cancer prevalence and better rate of diagnosis.

The rising incidence of radiation toxicity in the healthcare and chemical industries drives the need for appropriate therapy. Another key factor contributing to market expansion is the recent FDA approval of various orphan medications that have been shown to effectively boost the survival rate in adult and pediatric radiation sickness patients. These application areas continue to provide prospects for growth in the Global Radiation Toxicity Treatment Industry.

Key Takeaways – Radiation Toxicity Treatment Market Study

Increased use of colony-stimulating agents, such as Amgen’s Neulasta, will account for more than 75% of revenue share in the Radiation Toxicity Treatment market by 2029.
Non-ionizing radiation is expected to provide a lucrative opportunity to market participants due to high incidences of radiation toxicity caused by gamma radiation emission from positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scanners installed in hospitals and diagnostic centers.
North America continues to lead the Radiation Toxicity Treatment market, while South Asia is expected to rise rapidly soon.

Who Is Winning?

Some of the key players operating in the Global Radiation Toxicity Treatment Industry include Amgen Inc., Partner Therapeutics, Mylan N.V., and Novartis AG. Leading players in the Global Radiation Toxicity Treatment Industry are focusing on acquiring smaller companies to enhance their product portfolio and improve regional market positioning.

For instance, Siegfried Group announced the acquisition of a drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Also, in 2018, Partner Therapeutics (PTx) acquired global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

More insights available

North America is expected to dominate the radiation toxicity market due to the high incidence of cancer in the region, favorable reimbursement policies, and well-established healthcare infrastructure. Europe is also expected to witness significant growth in the radiation toxicity market due to increasing government initiatives to promote radiation therapy and rising investments in research and development activities.

Radiation Toxicity Treatment Market by Category

By Product:

Colony Stimulating Factors
Potassium Iodide
Prussian Blue
Diethylenetriamine Pentaacetic Acid
Others

By Indication:

Acute Radiation Syndrome
- Bone Marrow Syndrome (Hematopoietic)
- Gastrointestinal Syndrome (GI)
- Cardiovascular (CV)
Chronic Radiation Syndrome

By Radiation Type:

Ionizing Radiation
- Alpha Radiation
- Beta Radiation
- Gamma Radiation
Non-ionizing Radiation

By End-User:

Hospitals
- Government Hospitals
- Private Hospitals
Research & Academic Institutes
- Government Research and Academic Institutes
- Private Research and Academic Institutes

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Implantable Drug Eluting Devices Market Projected to Grow at a 6.0% CAGR, Reaching an Estimated USD 12.8 Billion by 2029

The global implantable drug eluting devices market is poised for significant growth, expected to expand at a compound annual growth rate (CAGR) of 6.0% from 2022 to 2029. The market was valued at approximately USD 12.8 billion as of 2022, highlighting a robust demand for innovative medical solutions that enhance therapeutic efficacy.

According to projections from Future Market Insights, contraceptive drug eluting devices accounted for a substantial market share of over 39.8% in 2021, underscoring their importance within the broader landscape of implantable drug delivery systems. These devices are increasingly recognized for their ability to provide sustained release of medication, improving patient adherence and outcomes.

Key factors driving growth in the implantable drug eluting devices market include:

Rising Demand for Long-Acting Contraceptive Solutions: The growing awareness and acceptance of long-acting contraceptive methods are contributing to the increased adoption of drug eluting devices, particularly in reproductive health.
Technological Advancements: Innovations in drug eluting technologies, including improved formulation and delivery mechanisms, are enhancing the effectiveness and safety of these devices, attracting healthcare providers and patients alike.
Growing Prevalence of Chronic Diseases: The rising incidence of chronic diseases, such as cardiovascular conditions and cancer, is propelling the need for effective drug delivery systems that provide targeted therapy and minimize side effects.
Expanding Healthcare Infrastructure: The development of healthcare infrastructure in emerging economies is facilitating access to advanced medical technologies, further boosting the adoption of implantable drug eluting devices.

As the market continues to evolve, industry stakeholders are encouraged to invest in research and development to create innovative solutions that address the diverse needs of patients and healthcare providers.

Among the various product categories, contraceptive drug eluting devices have demonstrated significant market presence, holding a substantial share of over 39.8% in 2021. These devices provide a reliable and effective means of contraception, contributing to their growing adoption worldwide.

A significant contributor to this growth is the substantial market share held by contraceptive drug eluting devices, which represented over 39.8% of the market in 2021. This highlights the growing adoption of implantable devices for contraceptive purposes, driven by their effectiveness and convenience in long-term birth control.

In a noteworthy trend, manufacturers leading the industry are harnessing advancements in micro and nanotechnology to craft innovative implantable drug-eluting devices, steering the industry towards unprecedented growth. These cutting-edge devices exhibit controlled and site-specific attributes, along with compatibility for targeted drug delivery. This unique combination not only simplifies intricate dosing schedules but also mitigates the systemic toxicity associated with conventional drug delivery systems.

Remote-Controlled Chips and Programmable Devices – Future of Targeted Drug Delivery

Increasing clinical trials and research & development of remote-controlled and programmable drug-eluting devices Massachusetts Institute of Technology (MIT) researchers have developed a remote-controlled contraceptive hormone (levonorgestrel) delivery chip implant, which can turn the device on and off. Implantable drug-eluting devices allow minimum effective doses and support oral opioid weaning

Implantable drug-eluting devices such as SynchroMed II intrathecal drug delivery system with a controlled workflow system, play an effective role in reducing or eliminating the use of oral opioids. Antiretroviral (ARV) drug implant is expected to emerge as a promising approach for HIV treatment and prevention In July 2022, Merck & Co. started the development of slow-release antiretroviral (ARV) drug implants as a promising approach for HIV treatment.

The growth of the Global Implantable Drug Eluting Devices Industry can be prominently attributed to the associated cost-effective technology and novel medication administration techniques. Fewer side effects while these devices are utilized in the management of chronic diseases as well as in contraception have been the strongest attribute accounting for a steadily expanding market for implantable drug-eluting devices. Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Know More About Global Implantable Drug-Eluting Devices Industry Report

The Global Implantable Drug-Eluting Devices Industry, a new study from Future Market Insights, opines on the evolution of the implantable drug-eluting devices market from 2014 – 2021 and presents demand projections from 2022 – 2029 based on product type (implantable drug infusion pumps, intraocular drug-eluting devices, contraceptive drug-eluting devices, buprenorphine implant, and drug-eluting stents), technology (active drug-eluting devices and passive drug-eluting devices) applications (diabetes macular edema, birth control/contraception, opioid addiction, cardiovascular, ophthalmology, oncology, pain management, others) implantation type (intravaginal, intravascular, intraocular, intrathecal, subcutaneous, intrauterine) end users (hospitals, ambulatory surgical centers, optical care centers, cardiac surgery centers, office-based setting, and others) in seven prominent regions.

Medical-Pharma Collaborating to Balance Demand and Supply

A comprehensive view of the Global Implantable Drug Eluting Devices Industry has led our analysts to conclude that, the market is expected to grow at an impressive rate. This market growth is mainly attributed to increasing innovations and developments in implantable drug-eluting devices for the management and treatment of breast cancer, schizophrenia, Parkinson’s disease, and photosensitivity diseases. Besides, FMI analyst suggests that markets in North America and Europe are expected to hold major value shares in the global implantable drug-eluting devices landscape. Medical device companies are collaborating with pharmaceutical companies to develop efficient drug-delivery devices to cater to the rising demand for implantable drug-eluting devices.

Increasing use of syringe-based subcutaneous implantable drug-eluting devices is anticipated to minimize the number of invasive surgical procedures. The introduction of implantable drug-eluting devices or rare conditions such as central precocious puberty (CPP) will emerge as an important factor shaping the market for implantable drug-eluting devices.

A Old Full Report Analysis Click Here

Key Segments Covered in Global Implantable Drug-Eluting Devices Industry Research

By Product:

Implantable Drug Infusion Pumps
Intraocular Drug-Eluting Devices
Contraceptive Drug-Eluting Devices
Buprenorphine Implant
Drug-Eluting Stents
Others

By Technology:

Active Drug Eluting Device
Passive Drug Eluting Device
- Biodegradable Implants
- Non-Biodegradable Implants

By Application:

Diabetic Macular Edema
Birth Control/Contraception
Opioid Addiction
Cardiovascular
Ophthalmology
Oncology
Pain Management

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Pressure Infusion Bags Market Expected to Reach USD 494.5 Million by 2029 at a 6.5% of CAGR

The global pressure infusion bags market was valued at approximately USD 300.0 million in 2021 and is projected to reach USD 494.5 million by 2029, according to a recent market survey conducted by Future Market Insights (FMI). This significant growth underscores the increasing demand for pressure infusion bags in healthcare settings.

Pressure infusion bags are essential medical devices used to administer fluids rapidly and effectively during critical situations, such as surgery or trauma care. Their importance in patient management and fluid resuscitation is driving their adoption across hospitals, clinics, and emergency medical services.

Key factors contributing to the anticipated growth of the pressure infusion bags market include:

Rising Demand for Emergency Medical Services: The growing number of emergency medical situations, coupled with an increasing focus on timely patient care, is driving the demand for efficient fluid administration solutions.
Technological Advancements: Innovations in the design and functionality of pressure infusion bags, such as improved pressure control mechanisms and user-friendly features, are enhancing their effectiveness and appeal to healthcare providers.
Increasing Healthcare Expenditure: The expansion of healthcare infrastructure and rising healthcare expenditures globally are facilitating the adoption of advanced medical devices, including pressure infusion bags.
Growing Awareness of Patient Safety: The heightened emphasis on patient safety and care quality is prompting healthcare professionals to invest in reliable infusion solutions that enhance patient outcomes.

As the pressure infusion bags market continues to evolve, industry stakeholders are encouraged to focus on innovation and quality to meet the growing demands of healthcare providers and improve patient care.

Pressure infusion bags are critical in emergency and surgical environments, facilitating rapid fluid infusion to patients. The rising prevalence of chronic diseases and the growing need for emergency medical services are driving the demand for these essential devices.

The anticipated growth in the pressure infusion bags market is driven by increasing demand for efficient and effective infusion solutions in medical procedures. Pressure infusion bags are crucial for administering fluids rapidly and precisely, which is vital in emergency care and surgical settings.

Pressure infusion cuffs are designed cuff and bladder device used to pressurize sterile parenteral fluids for rapid infusion into the body. These decrease the infusion time to a few seconds from hour taken by gravity fed blood infusion. The need for rapid infusion of solutions and monitoring of invasive procedures involving pressure are the prime applications of pressure infusion bags. The growing frequency of intra-arterial pressure monitoring and Swan Ganz catheterization procedures coupled with the need to retard the retrograde flow of blood is driving a large market adoption. The development of healthcare infrastructure especially trauma care units, intensive care units, and ambulatory surgical centers are driving a large market expanse.

Key Players

Some of the major players in the global pressure infusion cuffs market are VBM Medizintechnik GmbH, ERKA, SSEM Mthembu Medical (Pty) Ltd., Smiths Medical (Smiths Group plc.), Friedrich Bosch GmbH & Co. KG, Biegler GmbH, SARSTEDT AG & Co. KG and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Pressure Infusion Cuffs Market: Drivers and Restraints

The development of technology such as the flush valve for regulating the flow of solution coupled with the miniaturization of monitoring devices, ergonomically design, growing use of polyester and nylon material and others is driving a large market. The growing cases of blood transfusion in emergencies coupled with the growing population of geriatric and immunocompromised population is driving a large market.

The restraints on the global pressure infusion cuffs market are the pressure on pricing owing to large market fragmentation, the high volume low value nature of the market which results in price being the most significant value proposition, lack of standardization, low awareness and others.

Pressure Infusion Cuffs Market: Regional Wise Outlook

The global pressure infusion cuffs market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Asia Pacific market excluding Japan is expected to account for the largest share of the global pressure infusion cuffs market owing to expanding healthcare sector and use of medical devices, and the emergence of China as a large manufacturing base for medical devices. China and India are expected to drive a lion’s share of the pressure infusion cuffs market.

The North America pressure infusion cuffs market is expected to generate a sluggish growth owing to saturation with US leading the pressure infusion cuffs market. Europe market is led by Germany, France and the UK and is expected to be the third largest market.

The Middle East and Africa pressure infusion cuffs market is expected to be dominated by the gulf economies of Saudi Arabia, Kuwait, and Qatar. The poor healthcare expenditure of Africa is a deterrent of the growth of pressure infusion cuffs market.

The report covers exhaust analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

A Old Full Report Analysis Click Here

Pressure infusion cuffs Market: Segmentation

To gain an accurate understanding of the latest market trends of the global pressure infusion cuffs market, the report is segmented based on applications, coupling mechanism, connectivity mechanism, material of construction, utility, design, end user, and region.

Based on applications, the global pressure infusion cuffs market is segmented into the following:

Blood and Blood Products
Irrigation
Others

Based on size, the global pressure infusion cuffs market is segmented into the following:

Up to 500 ml
Up to 1000 ml
Greater than 1000 ml

Based on material of construction, the global pressure infusion cuffs market is segmented into the following:

Rubber
Polymers
Others

Based on utility, the global pressure infusion cuffs market is segmented into the following:

Disposable
Reusable

Based on end user, the global pressure infusion cuffs market is segmented as below:

Hospitals
Clinics
Ambulatory Surgical Centers

Author By:

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Surgical Tourniquet Market Projected to Reach USD 905.1 Million by 2034, Growing at a CAGR of 5.2%

The global surgical tourniquet market is set to experience significant growth, with an estimated worth of USD 545.1 million by 2024. Projections indicate that the market will continue to expand, reaching a value of USD 905.1 million by 2034, representing a robust compound annual growth rate (CAGR) of 5.2% during the forecast period.

Surgical tourniquets play a critical role in medical procedures, providing essential blood control and enhancing surgical efficiency. The increasing number of surgical procedures globally, coupled with advancements in healthcare technologies, is driving the demand for these vital medical devices.

Key factors contributing to the growth of the surgical tourniquet market include:

Rising Surgical Procedures: The growing prevalence of chronic diseases and an aging population are leading to an increase in surgical interventions, thereby boosting the demand for surgical tourniquets.
Technological Innovations: Advancements in tourniquet technology, including improved safety features and ease of use, are attracting healthcare providers seeking efficient solutions for blood management during surgeries.
Growing Awareness: Increased awareness about the importance of proper blood control during surgical procedures is leading to higher adoption rates of surgical tourniquets among medical professionals.
Expanding Healthcare Infrastructure: The development of healthcare infrastructure, particularly in emerging economies, is facilitating access to advanced surgical devices, further driving market growth.

As the surgical tourniquet market continues to evolve, industry stakeholders are encouraged to invest in research and development to enhance product offerings and meet the growing demands of healthcare providers.

To mitigate the risks associated with elevated tourniquet pressures, manufacturers are directing their focus toward product innovations. They are introducing novel features such as automatic pressure control, audiovisual alarms, digital displays, and user-friendly interfaces, aiming to enhance the safety and effectiveness of these medical devices.

Sales of Tourniquet Cuffs to Ramp up in 2019

According to the FMI analysts, tourniquet cuffs have been a vital part of the modern computer-assisted tourniquet system, which accounted for ~77% of total market revenue in 2018. While the inflatable disposable cuffs represented more than half of the total tourniquet cuff sales in 2018, the consumption of inflatable reusable cuffs is likely to increase by 7.6% y-o-y in 2019.

“In terms of tourniquet systems, dual channel systems will continue to represent a relatively high share as compared to single channel systems, in the view of enabling bi-lateral procedures or simultaneous surgeries of both upper and lower extremity,” the FMI analyst said.

The consumption of surgical tourniquets for knee arthroplasty accounted for ~31% of sales in 2018, while increasing application in the amputation of limbs and trauma cases is likely to result in increased market share in the future.

“Recent advancements in reverse shoulder arthroplasty along with the introduction of ‘personalized’ tourniquet systems that allow the use of variable contour design and cuffs for specific patients will open new avenues of growth for the market players,” said the FMI analyst.

Hospitals Capture Significant Share, North America in the Vanguard

In 2018, surgical tourniquets worth ~US$ 176 million were sold in hospitals; according to FMI analysts, a growing number of hospitals, especially in developing countries, and greater awareness of advanced medical devices will continue to drive the consumption of surgical tourniquets in hospitals.

The rapid adoption of the ‘value-based’ model in health care settings has led to a surge in the number of ambulatory surgical centers and specialized clinics, thereby paving a new way of growth for the surgical tourniquets market.

The FMI analyst forecasts that North America will continue to remain at the forefront of the surgical tourniquets market, representing a 30% share in 2018. While North America is likely to be neck-and-neck with Europe to lead the market in the future, manufacturers are tapping into new opportunities in developing countries in the Asia Pacific.

The surgical tourniquets market shows a fair level of fragmentation, with two prominent players Zimmer Biomet and Stryker Corporation accounting for more than one-third of the total revenue share. Exploring unmet needs in developing regions and expanding their distribution through collaboration and acquisitions of local and regional manufacturers remain key focal points of the market players.

A Old Full Report Analysis Click Here

Key Segment

By Product Type

Tourniquet Systems
- Single Channel Systems
- Dual Channel Systems
Tourniquet Cuffs
Inflatable Cuffs
- Disposable Cuffs
- Reusable Cuffs
Non-Inflatable Cuffs
- Disposable Cuffs
- Reusable Cuffs

By Application

Knee Arthroplasty
Amputation of Limbs
Plastic Surgeries
Trauma Cases

By End User

Hospitals
Ambulatory Surgical Centers
Specialized Clinics

By Region

North America
Europe
Latin America
South Asia
East Asia
Oceania
Middle East And Africa
Emerging Countries

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Vacuum Mixing Devices Market Projected to Grow at a 2.4% CAGR, Reaching an Estimated USD USD 186.0 Million by 2029

The global Vacuum Mixing Devices Market is poised for substantial growth, with an expected compound annual growth rate (CAGR) of 2.4% from 2022 to 2029. The market value was estimated at approximately USD 157.9 million as of 2022, indicating a positive outlook for the industry.

According to projections by Future Market Insights, vertical vacuum-mixing devices commanded a significant share of over 57.7% in the global market in 2021. This segment’s dominance is attributed to its efficient mixing capabilities and versatility, making it a preferred choice across various applications, including pharmaceuticals, cosmetics, and food production.

The FMI analyst is of the opinion that market gains will further be upheld by the clinical benefits associated with use of vacuum mixing devices. FMI expects the vacuum mixing devices to see unwavering growth in the next 10 years, as the global healthcare space actively embraces ‘efficiency-enabling’ medical mixing equipment.

Medical mixing processes have remained challenging for a long period of time, primarily undermined by the lack of competent technologies. With gradual evolution of vacuum mixing devices, a wide range of mixing applications are handled seamlessly in shorter timespan without compromising on the results.

According to the FMI report, the vacuum mixing devices market reflects a fair degree of fragmentation, wherein a large pool of regional manufacturers is competing neck to neck. Stryker Corporation and Zimmer Biomet remain two of the market goliaths, with strong product portfolios and extended regional presence.

A majority of the revenues of these two companies are generated from the US and Germany, and their focus on strategic collaborations will continue to yield significant profit benefits and ensure sustained growth. For instance, in 2018, Zimmer Biomet Holdings, Inc. – a global leader in musculoskeletal healthcare – collaborated with Apple to transform the patients’ journey for two most common type of surgeries undergone by the Americans every year – knee and hip replacement. This collaboration was aimed at popularizing the Zimmer Biomet ‘mymobility’ app, an app that makes use of Apple Watch to facilitate constructive connections between patients and their respective surgical teams.

The FMI analyst finds that though the factors conditioning success differ for market players of varying statures, but in all the cases, the market partakers will have to be adept at effective tracking of the evolving market trends and make necessary adaptations.

Key Companies Profiled:

Zimmer Biomet
Heraeus Holding
Stryker
DJO Global, Inc.
Summit Medical
OSARTIS GmbH
SIRIO DENTAL S.R.L.
DENTALFARM SRL
Eurocem Srl
Whip Mix Corporation

Portability: The New Normal Grappling End User Appeal

In 2018, the devices with vertical orientation is estimated to surpass other variants and account for over ½ of the global vacuum mixing devices-derived value. Though end users will continue to invest in vertical vacuum mixing devices, the demand for rotational vacuum mixing devices will also see a considerable uptick through 2029, unveils FMI.

With ‘portable’ emerging as the new norm in the medical laboratory equipment space, manufacturers are jumping onto the ‘portability’ bandwagon by launching newer models of vacuum mixing devices that are easy-to-carry and compact in size. According to the FMI analysis, North America (29%) and Europe (26%) will continue to be the leading markets for vacuum mixing devices in 2019 and beyond, set in motion by robust healthcare infrastructure and massive investments in development of high-quality laboratory essentials.

Vacuum mixing devices worth ~ US$ 128 Mn were sold in hospitals in 2018, primarily driven by the growing number of inpatient and outpatient procedures. Manufacturers, to draw upon this increase in demand, are focusing on effective marketing of their products to hospitals by using ‘easy-to-use’ and ‘compatibility with varying viscosities’ as two of their key marketing touchpoints. However, various regulations put in place for manufacturing of vacuum mixing devices will continue to impede its penetration by increasing the ‘time-to-market’ factor.

Key Market Segments Covered in Vacuum Mixing Devices Industry Research

By Product:

Vertical Vacuum-Mixing Devices
Rotational Vacuum-Mixing Devices
Vertical+Twisting Vacuum-Mixing Devices

By Modality:

Bench Top Devices
Portable Devices

By End User:

Ambulatory Surgical Centers
Hospitals
Specialty Clinics

Author by

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Micro Display Market Poised for Significant Growth: Key Trends and Forecasts for 2023 to 2033

The micro display market is expected to develop significantly over the next ten years, with a compound annual growth rate (CAGR) of 19.2% from 2023 to 2033, when its value is expected to rise from USD 1.4 billion to USD 8.2 billion. One of the main factors driving this rise is the growing need for augmented reality (AR) and virtual reality (VR) devices, as well as the growing use of these technologies in the consumer electronics, automotive, and defense industries.

Micro displays, which are renowned for their small size and high pixel density, are increasingly being used in a wide range of technologies, from head-up displays (HUDs) in cars to smart eyewear. Improved user experiences are made possible by these developments, which are also expected to hasten the adoption of tiny screens across a range of industries.

Key Takeaways from Market Study

The Micro Display Market is forecast to grow from US$ 1.4 billion in 2023 to US$ 8.2 billion by 2033, achieving a CAGR of 19.2%.
AR/VR devices and automotive HUDs are key growth drivers as industries shift towards more immersive and connected technologies.
The Asia-Pacific region is expected to dominate the market, driven by strong demand in China and Japan, while North America will continue to see significant growth.
The increasing use of OLED and LCD technologies in micro displays is contributing to improved performance and wider applications.

Drivers and Opportunities

The rapid adoption of AR and VR technologies in industries such as entertainment, education, healthcare, and retail is a key factor driving the demand for micro displays. These displays are an essential component in smart glasses, head-mounted displays, and wearable devices, which are being used to provide immersive experiences for users.

The automotive industry is another significant growth driver, with an increasing focus on autonomous driving and driver-assistance systems. Head-up displays (HUDs), which project critical driving information onto the windshield, are becoming a standard feature in high-end vehicles. The integration of micro displays into these systems allows for sharper, clearer images, improving safety and user experience.

Moreover, the defense and military sectors are utilizing micro displays in night vision devices, thermal imaging systems, and helmet-mounted displays, offering opportunities for market expansion.

Components Insights

The Micro Display Market is segmented by display technologies, including OLED (organic light-emitting diode), LCD (liquid crystal display), and LCoS (liquid crystal on silicon). Among these, OLED technology is gaining traction due to its superior contrast ratios, faster response times, and lightweight design, making it ideal for use in AR/VR applications and wearable devices.

LCDs, while slightly less advanced than OLEDs, are still widely used in applications where cost efficiency is critical. LCoS technology is also utilized in projection systems and HUDs, offering high resolution and brightness, making it suitable for automotive and military applications.

Application Insights

Micro displays have found increasing applications across several industries. In the consumer electronics sector, they are used in smart glasses, smart watches, and virtual reality headsets, with demand expected to surge as these devices become more mainstream.

In the automotive industry, micro displays are integrated into head-up displays (HUDs), providing drivers with real-time navigation and safety data. This technology is becoming essential in luxury vehicles and is expected to trickle down to more affordable models as the technology matures.

The military and defense sector is another significant end-user of micro displays, utilizing them in night vision systems, thermal imaging, and military-grade HUDs, driving market demand further.

Deployment Insights

Micro displays are predominantly deployed in wearable technologies and HUDs across various industries. OLED micro displays, in particular, are becoming more prevalent due to their superior display quality and power efficiency.

The growing demand for portable and wearable electronic devices in both consumer and enterprise applications is pushing manufacturers to adopt OLED and LCoS technologies, which are best suited for compact, high-resolution displays.

Key Companies & Market Share Insights

The Micro Display Market is highly competitive, with key players such as Sony Corporation, Himax Technologies, Inc., Kopin Corporation, eMagin Corporation, and MicroOLED leading the market. These companies are focusing on research and development to improve the quality and performance of their displays while expanding their product portfolios to cater to emerging applications in AR/VR and automotive sectors.

Sony Corporation, a market leader, is leveraging its expertise in OLED technology to deliver high-performance micro displays for VR headsets and professional camera viewfinders. Himax Technologies and Kopin Corporation are also at the forefront of this innovation, providing micro displays for AR applications and wearable devices.

Recent Developments

Sony Corporation launched its latest generation of OLED micro displays, offering enhanced resolution and brightness for AR and VR devices, positioning itself as a leader in the growing market for immersive technologies.
Kopin Corporation announced advancements in LCoS micro displays, which are expected to enhance the capabilities of HUDs in both automotive and military applications.
eMagin Corporation expanded its production capacity to meet the rising demand for OLED micro displays, targeting the defense and consumer electronics markets.

Request a Sample of this Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-6186

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us:

Clinical Trial Market Projected to Reach USD 184.61 Billion by 2034, Growing at a CAGR of 4.3%

The global clinical trial market is poised for significant growth, with an estimated size of approximately USD 120.97 billion in 2024. Forecasts indicate that the market will continue to expand at a robust compound annual growth rate (CAGR) of 4.3% from 2024 to 2034, ultimately reaching an anticipated value of USD 184.61 billion by the end of the forecast period.

As the demand for innovative treatments and therapies increases, the clinical trial market plays a crucial role in advancing medical research and ensuring the safety and efficacy of new drugs and medical devices.

The growth in the clinical trial market is driven by increasing investment in drug development, a rising number of chronic diseases, and the need for new therapeutic solutions. Clinical trials are crucial for the advancement of medical research and the introduction of new drugs and treatments to the market.

The expected market growth is fueled by increasing investments in research and development, a growing focus on innovative therapies, and the rising demand for advanced clinical trials across various therapeutic areas. As pharmaceutical and biotechnology companies continue to prioritize clinical trials as a critical component of their development pipelines, the market is poised for robust expansion.

Both governmental and private sponsorship of clinical trials is helping them increase in number. As the number of diseases and patients increases, there is more demand for research to come up with newer medicines and treatments. The rise in cancer patients is especially necessitating the development of more oncology clinical trials.

Clinical trials are making use of advanced technology like AI and machine learning. These technologies are helping researchers handle data, select better samples, save time, and increase effectiveness. Technology is also allowing researchers conduct virtual trials, a holdover from the pandemic era that is still going strong.

There are, however, impediments to market growth. While more people are open to being a part of trials, sometimes researchers struggle to find the right candidates with the right symptoms or afflictions. The complex process of clinical trials, requiring significant funding, is also a roadblock in the path of the market.

Non-small cell lung cancer (NSCLC) and breast cancer were primarily targeted for clinical development among the numerous oncology indications. However, the market for oncology clinical trials is progressively getting more complicated in terms of patient recruitment, clinical trial design elements like outcomes, and more stringent eligibility requirements, among other things.

“Clinical trials are no longer relegated to just labs as decentralized trials that are more convenient for the subjects are emerging as a significant trend. Outsourcing lab work to countries like India and Brazil is also being practiced by companies from developed nations. Thus, outsourcing and decentralized trials represent significant opportunities in the market”, Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Key Takeaways from the Clinical Trial Market

The clinical trial market is projected to be valued at USD 120.97 billion in 2024.
Industry sponsorship is the prevailing mode of sponsorship in the market. In 2024, industry sponsorship is projected to account for 55.0% of the market share.
Oncology is the prime area of concern for clinical trials. For 2024, oncology is anticipated to account for 29.7% of the market share by area.
Germany is one of the most promising countries for the market. For the forecast period, the CAGR for Germany is estimated to be 5.6%.
The United Kingdom is another European country with a bright future for the market. The CAGR for the United Kingdom is anticipated to be 4.7% for the forecast period.
The market is expected to register a CAGR of 5.0% in the United States over the forecast period.

What are the Factors Restraining Demand for Clinical Trials?

Patients who match trial selection criteria have become harder to find for businesses. Additionally, the change in medication development efforts to new modalities is intensifying the competition for patients, which makes recruiting more difficult. The typical length of clinical trials has grown as a result of these considerations.

More specifically, as clinical studies move forward, more participants are needed, but the eligibility and appropriateness standards also rise. A patient’s medical history or a mismatch in the stage of their sickness compared to the study protocol may disqualify them from taking part. Patients who are eligible and suitable can find the criteria demanding or the recruitment procedure difficult and time-consuming, or they might not be aware of or compelled to participate.

Another barrier to participation is the cost of frequent clinic visits. The patient population that a novel therapy is anticipated to treat and those taking part in the associated clinical study are also at odds with one another. Patients who are thinking about taking part in a clinical trial for a new drug must balance the advantages of early access to a potential new therapy against the risks of adverse events, as well as the inconvenience, potential financial load, and time commitments.

Clinical trials often encounter challenges such as poor site selection, poor research design, poor trial execution, safety concerns, and dropouts owing to logistical or financial considerations. These factors cumulatively present a limiting impact upon the growth of the overall market during the forecast period.

Competition Analysis of the Clinical Trial Market

Companies in the market are taking the aid of both private and government sponsorships. The nature of the market is fragmented, with scope for organizations of all scales. Some prominent companies in the market include ICON plc, Charles River Laboratories International, Inc., IQVIA, and SYNEOS HEALTH.

Recent Developments in the Clinical Trial Market

In January 2024, Abbott announced the completion of the first trials of the company’s Volt Pulsed Field Ablation (PFA) System for the treatment of heart rhythm disorders.
In August 2023, LG Chem applied to the Italian Medicines Agency for Phase 3 trials of its gout treatment Tigulixostat.

Key Companies in the Clinical Trial Market

Pharmaceutical Product Development, INC. (Thermo Fisher Scientific, Inc.)
ICON plc
Charles River Laboratories International, Inc.
IQVIA
SYNEOS HEALTH
SGS SA
PAREXEL International Corporation
Wuxi AppTec, Inc
Chiltern International Ltd (Laboratory Corporation of America)
Eli Lilly and Company
Novo Nordisk A/S
Pfizer
Clinipace (Caidya)

Category-wise Insights

Which Clinical Trials Sponsor is Driving Market Growth?

The industry sponsor leads the market and the segment will hold a share of around 55% globally, in 2024.

For pharmaceutical and medical device businesses, faster clinical trials are essential because they require a lot of time and money. Due to their increasing complexity and requirement for a bigger patient pool, phase III clinical trials continue to cost more than phase II and phase I trials.

Sponsors are very inclined to believe that developing nations like South Asia and East Asia have more potential for success. Conducting clinical trials in these quickly expanding regions holds forth the possibility of a new range of benefits, including financial incentives and effective regulatory processes, thus benefiting the industry sponsor segment’s growth during the projected period.

What Area of Clinical Trials is Largely in Focus Globally?

The oncology segment will hold a global market share of around 29.7% in 2024.

The cancer therapeutic indication has seen the highest number of new drugs launched globally. The bulk of the leading industrial sponsors of clinical trials contributed significantly to the oncology medicine portfolio.

Among the several oncology indications, clinical development has primarily concentrated on non-small cell lung cancer (NSCLC) and breast cancer. Most firms chose oncology as their primary therapeutic focus since this therapeutic field saw a disproportionately large number of clinical studies begin in comparison to the rest of their individual portfolios. A small number of companies provided a range of therapeutic specializations. Growing interest in the area of oncology will propel the growth of this segment over the projected years.

A Old Full Report Analysis Click Here

Clinical Trial Market Key Segments

By Sponsor:

Industry
Government Organizations
Non-Government Organizations
Others
Associations

By Area:

Oncology
Infectious Diseases
Metabolic Diseases
Cardiovascular Diseases
Neuroscience
Respiratory Diseases
Others

By Phase:

Phase 1
Phase 2
Phase 3
Phase 4

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

Author by

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Female Stress Urinary Incontinence Treatment Device Market Projected to Reach USD 1,432.0 Million by 2034, with a CAGR of 6.4%

The female stress urinary incontinence treatment device market is on a robust growth trajectory, projected to be valued at approximately USD 770.0 million in 2024. By 2034, this market is anticipated to surge to an impressive USD 1,432.0 million, reflecting a compound annual growth rate (CAGR) of 6.4% during the forecast period from 2024 to 2034.

Stress urinary incontinence is a prevalent condition affecting millions of women worldwide, often leading to significant physical and emotional challenges. As awareness of this condition increases, so does the demand for effective treatment solutions, driving innovation in device development and market growth.

Female stress urinary incontinence, a common condition that affects millions of women worldwide, is driving the demand for effective treatment solutions. The market for SUI treatment devices is expected to grow due to increasing awareness, advancements in medical technology, and rising incidences of urinary incontinence among the aging population.

The increasing prevalence of stress urinary incontinence among women and the rising awareness of available treatment options are key factors driving this market expansion. As more women seek effective solutions to manage and alleviate the symptoms of SUI, the demand for advanced treatment devices is expected to rise.

A few medical conditions such as enlarged prostate, muscle damage, excess urine formation, multiple sclerosis, Parkinson’s disease, spinal cord injury, and loss of storage capacity in the rectum are also expected to boost the incidence of stress urinary incontinence among women, which is fuelling the demand for female stress urinary incontinence treatment devices.

The practice of using female stress urinary incontinence treatment devices has changed dramatically over the past decade. The number of procedures undertaken appears to be increasing, and the shift in relative numbers of different procedures has been remarkable. For instance, in England, the annual number of operations undertaken using female stress urinary incontinence treatment devices between 1997-1998 and 2005-2006 increased by 28%, despite a reduction of over 90% in the number of colposuspension and needle suspension procedures.

Healthy Revenue Growth Projected Through 2029

According to the latest research by FMI, the Global Female Stress Urinary Incontinence Treatment Devices Industry is estimated to have accounted for ~ US$ 560 Mn in terms of value in 2018. The report on the female stress urinary incontinence treatment devices market further projects that the Global Female Stress Urinary Incontinence Treatment Devices Industry is likely to grow at a CAGR of ~ 6% during the period 2019-2029.

However, due to the presence of a wide range of products in the Global Female Stress Urinary Incontinence Treatment Devices Industry , small players are gaining interest and are selling their products at a lower price. An increase in the penetration of private-label brands at much lower prices is expected to decrease the average overall price of female stress urinary incontinence treatment devices. This is likely to restrain the growth of the Global Female Stress Urinary Incontinence Treatment Devices Industry, as it is likely to hamper the demand for expensive products.

Rapid changes have taken place in developing countries over the past few years. The improper implementation of regulatory guidelines and the lack of proper healthcare infrastructure in developing regions, such as the Middle East & Africa, and Latin America, are among the factors that are expected to restrain the growth of the Global Female Stress Urinary Incontinence Treatment Devices Industry.

50% Revenue Shares Accounted by North America

The female stress urinary incontinence treatment devices market has been analyzed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa. North America, followed by Europe, is a prominent region in the Global Female Stress Urinary Incontinence Treatment Devices Industry . North America accounted for a revenue share of about 50% in 2018 in the female stress urinary incontinence treatment devices market. Europe also accounted for a prominent revenue share and is followed by East Asia in the female stress urinary incontinence treatment devices market.

The Global Female Stress Urinary Incontinence Treatment Devices Industry report tracks some of the key companies operating in female stress urinary incontinence treatment devices market, such as Boston Scientific Corporation, BD, Coloplast Corporation, Caldera Medical, and Ethicon US LLC (Johnson & Johnson Services, Inc.). The majority of the key regional players in the Global Female Stress Urinary Incontinence Treatment Devices Industry are highly focused on expanding their product connectivity and reach with the help of domestic distributors of female stress urinary incontinence treatment devices. Moreover, the manufacturers of female stress urinary incontinence treatment devices are focused on strengthening their businesses in high-growth markets, such as India, Japan, and China, by expanding their distribution and sales channels.

Key Segments Of Female Stress Urinary Incontinence Treatment Devices Industry Survey Global Female Stress Urinary Incontinence Treatment Devices Industry by Product Type:

Sling Systems
- Mid-Urethral Slings
- Sub-Urethral Slings
Pessaries
Artificial Urinary Sphincters (AUS)
Injectable Urethral Bulking Agents

Global Female Stress Urinary Incontinence Treatment Devices Industry by End Use:

Female Stress Urinary Incontinence Treatment Devices for Hospitals
Female Stress Urinary Incontinence Treatment Devices for Gynaecological Clinics
Female Stress Urinary Incontinence Treatment Devices for Homecare Settings

Global Female Stress Urinary Incontinence Treatment Devices Industry by Region:

North America Female Stress Urinary Incontinence Treatment Devices Market
Latin America Female Stress Urinary Incontinence Treatment Devices Market
Europe Female Stress Urinary Incontinence Treatment Devices Market
East Asia Female Stress Urinary Incontinence Treatment Devices Market
South Asia & Pacific Female Stress Urinary Incontinence Treatment Devices Market
Middle East & Africa (MEA) Female Stress Urinary Incontinence Treatment Devices Market

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Surgical Booms Market Expected to Exceed USD 380.2 Million by 2029 at a 4.7% of CAGR

The global Surgical Booms Market has demonstrated significant growth, with a size of approximately USD 276.0 Million in 2022. As hospitals and ambulatory surgical centers increasingly adopt modern equipment management systems, the market is projected to experience steady growth at a compound annual growth rate (CAGR) of 4.7% from 2022 to 2029. By the end of this forecast period, the market is anticipated to surpass a valuation of USD 380.2 Million.

Surgical booms play a crucial role in enhancing the efficiency of surgical environments by providing easy access to medical equipment and improving the overall workflow in operating rooms. The rising demand for advanced surgical solutions, along with the focus on improving patient care and safety, is driving the adoption of these systems across healthcare facilities.

Increase in the Adoption of Minimally Invasive Surgeries is Likely to Drive the Growth of the Global Surgical Booms Industry

Minimally Invasive Surgery (MIS) is one of the major trends in medicine. MIS is a safe, feasible, and patient-friendly method of performing medical procedures such as surgery. MIS offers reduced postoperative pain, shorter length of stay in a hospital, lesser scarring or damage to tissues, and generally leads to faster recovery. Hence, MIS is easier and less time-consuming. As clinicians seek safer and more efficient ways to perform surgery, they find new applications for minimally invasive procedures, because the benefits of the same for patients are paramount. Furthermore, the increasing number of insurance providers that offer reimbursement for costs incurred during most minimally invasive procedures is expected to increase the adoption rate of minimally invasive surgeries. The Centers for Medicare and Medicaid Services (CMS) provides reimbursement for peripheral access procedures, such as the insertion of a port or catheter into a large central artery that is directly related to or is near the heart. Thus, increase in the number of minimally invasive surgeries is boosting the demand for equipment management systems such as equipment booms.

High Capital Investment for Integrated OR to Hinder the Growth of the Global Surgical Booms Industry

Integrated ORs utilise a crossover of medical interventions to form hybrid technologies. The development and integration of ORs requires the re-organization of professionals. In addition, there is a need to upgrade the capital equipment. Cost of such advanced capital equipment is high. Furthermore, compatibility with existing or new devices/infrastructure is likely to present a hurdle for the designers, manufacturers, and end users of surgical booms. A hybrid OR, on an average, requires 50-80% more space as compared to a conventional OR in the U.S., and 30-40% more in Germany. The additional space required is another factor that is likely to increase the cost of the setup of an integrated OR. Thus, the capital cost required for an integrated OR is likely to hinder the growth of the Global Surgical Booms Industry.

Global Surgical Booms Industry: Segmental Analysis

The Global Surgical Booms Industry has been segmented based on product, installation, and end user. Based on product type, the surgical booms market has been segmented into equipment booms, utility booms, anaesthesia booms, and custom booms. Custom booms lead the market due to the flexibility of choice the customers have from manufacturers. Based on installation, the Global Surgical Booms Industry has been segmented into roof mounting and floor mounting. In terms of revenue, the roof mounting segment is expected to have a major share in the surgical booms market during the forecast period as these are more flexible and conserve space in the OR more effectively. Based on end user, the Global Surgical Booms Industry has been categorised into hospitals, ambulatory surgical centres, specialty clinics, and hybrid operating rooms. The revenue generated by the hospitals segment of the surgical booms market is expected to witness significant growth, which is driven by the presence of a large number of ORs and associated ICU departments at various hospitals.

Global Surgical Booms Industry: Companies

Some of the key players in the Global Surgical Booms Industry include

CV Medical LLC.
Stryker Corporation
Hill Rom Holdings Inc.
Amico Group of Companies
Steris Plc
Ondal Medical Systems GmbH
Getinge Group
Pratibha Medinox
Skytron LLc
Palakkad Surgical Industries
among others.

Global Surgical Booms Industry Taxonomy

By Product

Equipment Booms
Utility Booms
Anesthesia Booms
Custom Booms

By End User

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Hybrid Operating Rooms

By Installation

Roof Mounting
Floor Mounting

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Afric

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

NFC Tag ICs Market Poised for Impressive Expansion: Forecasts 15.7% CAGR and US$ 50,175.2 Million Valuation by 2033

The global NFC tag ICs market is estimated to reach US$ 11,638.8 million in 2023, expanding at a CAGR of 15.7% from the forecast period 2023 to 2033. Moreover, the growing requirement for customers to exchange connections, transactions, and digital content via various electronic devices is expected to drive the industry.

According to the FMI report, the sales in the NFC tag integrated circuits (ICs) market are projected to reach a value of approximately US$ 50,175.2 million by the year 2033. This growth is primarily driven by the rapid expansion of the digital economy, which is expected to motivate manufacturers to make substantial investments in digital advancements and transition towards automated business models.

One of the critical variables expected to boost the global NFC tag ICs market growth in the approaching decade is key manufacturers’ increased focus on improving customer experience. Furthermore, increased wearable technology usage and smartphone proliferation in both advanced and developing nations are likely to bode well for the worldwide market.

The introduction of smartphones with NFC-based SOS functionality is also expected to boost growth. These capabilities allow users to scan their cell phones to send an SOS alert to someone engaged in an accident or in a critical situation, as well as offer the user’s medical records.

Companies are expected to incorporate NFC tag ICs on sealed medicinal packaging, allowing caretakers and doctors to check prescriptions and dose details via smartphones.

In terms of region, North America is expected to have a significant market share for NFC tag ICs in the approaching years. The swiftly growing popularity of the retail sector in the United States and Canada is expected to contribute to market development in the region.

Key Takeaways from the NFC Tag ICs Market Report:

The NFC Tag ICs market has shown significant growth over the past five years, with a Compound Annual Growth Rate (CAGR) of 13.6%. Projections indicate that India is poised for substantial development at a CAGR of 16.1% in the coming years. North America has maintained its dominance in the global market, capturing more than 27.4% of total sales. Notably, the medium memory segment (1000 to 10000 bytes) constituted the largest share, accounting for 45.5% of the market in 2022. Furthermore, China is expected to exhibit robust growth with a projected CAGR of 12.1%. These trends underscore the expanding adoption and significance of NFC Tag ICs across various regions, signaling promising opportunities for industry players and stakeholders.

Competitive Landscape:

The growing popularity of novel NFC applications, such as NFC-enabled smart sensors, smart automobiles, and smart posters among technically savvy and young clients, is likely to open up new growth prospects for market competitors. For example,

Identiv, Inc. (NASDAQ: INVE), a global leader in digital safety and detection in the Internet of Things (IoT), disclosed in May 2023 the addition of novel STMicroelectronics (ST) near-field communication (NFC) tags in specific form aspects to its bitse.io IoT system for tag determining and launching brand experiences.

In February 2023, STMicroelectronics hosted a webinar on the usage of NFC dynamic tags to simplify the process of incorporating novel IoT equipment into a current system in smart houses and other smart buildings.

Leading Key Players:

The NFC Tag ICs market is driven by key players such as Mstar Semiconductor Inc., Panasonic Corporation, Qualcomm Inc., STMicroelectronics, Nokia Corporation, NXP Semiconductors, MediaTek Inc., Broadcom Inc., Sony Corp., and Identive. With their innovative technologies and expansive product portfolios, these companies play pivotal roles in advancing NFC technology, catering to diverse industry needs and driving adoption across various sectors worldwide.

A more valuable insight into the NFC Tag ICs Market:

Future Market Insights, in its new offering, presents an unbiased analysis of the global NFC Tag ICs market presenting a historical analysis from 2018 to 2022 and forecast statistics between 2023 and 2033. The study reveals essential insights By Memory ((High (More than 10000 Bytes), Medium (1000 to 10000 Bytes), Low (Less than 1000 Bytes)), By Connection (People-To-People (Peer-to-Peer), People-To-Devices (Device Pairing)), By Application (Smart Posters, Payment, Marketing, Information, Content, Social Networking, Gaming, Validation), By Industry (BFSI, Media & Entertainment, Retail, Hospitality, Healthcare, Others) & region.

Request for a Sample of this Research Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-8583

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us: